Teva and Regeneron partner in $250m deal

22-09-2016

Teva and Regeneron partner in $250m deal

Photo: Courtesy of Teva

Teva and Regeneron Pharmaceuticals have combined to develop and commercialise fasinumab, a novel nerve growth factor (NGF) antibody.


Teva, Regeneron, fasinumab, antibodies, commercial deal

LSIPR